# reload+after+2024-01-20 16:44:31.829766
address1§2155 Park Boulevard
city§Palo Alto
state§CA
zip§94306
country§United States
phone§650 272 6138
fax§650 618 1621
website§https://www.eigerbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
fullTimeEmployees§56
companyOfficers§[{'maxAge': 1, 'name': 'Dr. David  Apelian M.B.A., M.D., Ph.D.', 'age': 58, 'title': 'CEO & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 204386, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jeffrey S. Glenn M.D., Ph.D.', 'age': 60, 'title': 'Scientific Founder & Independent Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 67000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Eldon C. Mayer III, M.B.A.', 'age': 62, 'title': 'Chief Commercial Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 586963, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. William G. Kaichoff CPA', 'age': 57, 'title': 'CFO and Principal Financial & Accounting Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher A. Kurtz', 'age': 56, 'title': 'Chief Technical Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James  Vollins J.D.', 'age': 54, 'title': 'General Counsel, Chief Compliance Officer & Corporate Secretary', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Colin  Hislop M.D., MBBS', 'age': 65, 'title': 'Senior Vice President of Clinical & Development Operations', 'yearBorn': 1958, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Colleen  Craig M.D.', 'title': 'Senior Vice President of Metabolic Diseases', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§4
boardRisk§7
compensationRisk§10
shareHolderRightsRisk§7
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.002
priceToSalesTrailing12Months§0.022001637
currency§USD
dateShortInterest§1702598400
forwardEps§-0.52
exchange§NGM
quoteType§EQUITY
shortName§Eiger BioPharmaceuticals, Inc.
longName§Eiger BioPharmaceuticals, Inc.
firstTradeDateEpochUtc§1391092200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f40195ae-deeb-3177-beb3-ef4809e78599
gmtOffSetMilliseconds§-18000000
targetHighPrice§5.0
targetLowPrice§1.0
targetMeanPrice§3.0
targetMedianPrice§3.0
recommendationMean§1.0
recommendationKey§strong_buy
numberOfAnalystOpinions§3
quickRatio§2.769
grossMargins§0.98173
ebitdaMargins§0.0
trailingPegRatio§None
